<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.onclive.com/view/onclive-weekly-news-quiz-11-20-2026-did-you-miss-crucial-lung-cancer-pcnsl-gastroesophageal-cancer-and-aml-updates-</loc>
      <lastmod>2026-11-20T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T14:00:00Z</news:publication_date>
        <news:title><![CDATA[OncLive Weekly News Quiz (11/20/2026): Did You Miss Crucial Lung Cancer, PCNSL, Gastroesophageal Cancer, and AML Updates?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/real-world-outcomes-and-treatment-management-with-car-t-cell-therapy-in-cll</loc>
      <lastmod>2026-11-20T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Real-World Outcomes and Treatment Management With CAR T-Cell Therapy in CLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/her2-mutant-nsclc-destiny-lung04-and-first-line-t-dxd-efficacy</loc>
      <lastmod>2026-11-20T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:05:00Z</news:publication_date>
        <news:title><![CDATA[HER2-Mutant NSCLC: DESTINY-Lung04 and First-Line T-DXd Efficacy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/comparing-toxicity-profiles-and-treatment-considerations-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-20T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Comparing Toxicity Profiles and Treatment Considerations in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/hpv-testing-with-p16-and-confirmatory-assays</loc>
      <lastmod>2026-11-20T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:05:00Z</news:publication_date>
        <news:title><![CDATA[HPV Testing With p16 and Confirmatory Assays]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/48-month-survival-analysis-of-the-benefit-trial-isatuximab-plus-bortezomib-lenalidomide-and-dexamethasone-for-transplant-ineligible-newly-diagnosed-multiple-myeloma-patients</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[48-Month Survival Analysis of the BENEFIT Trial, Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/soho-01-updated-efficacy-and-safety-of-sevabertinib-in-advanced-her2-mutant-nsclc-including-first-line-patients-pts-and-those-with-active-brain-metastases</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[SOHO-01: Updated efficacy and safety of sevabertinib in advanced HER2-mutant NSCLC, including first-line patients (pts) and those with active brain metastases]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/hpv-biology-and-rational-egfr-partner-targets</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[HPV Biology and Rational EGFR Partner Targets]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/her2-mutant-nsclc-trastuzumab-deruxtecan-for-her2-overexpression</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[HER2-Mutant NSCLC: Trastuzumab Deruxtecan for HER2 Overexpression]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/outcomes-with-first-line-obrixtamig-plus-standard-of-care-in-epnec-by-dll3-expression-status-phase-ib-dareon--7-study</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Outcomes with First-Line Obrixtamig Plus Standard of Care in epNEC by DLL3 Expression Status: Phase Ib DAREON®-7 Study]]></news:title>
        <news:keywords><![CDATA[colorectal cancer,CRC,mCRC]]></news:keywords>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/efficacy-of-car-t-cell-therapy-in-relapsed-refractory-cll</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Efficacy of CAR T-Cell Therapy in Relapsed/Refractory CLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/belantamab-mafodotin-in-daratumumab-exposed-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Belantamab Mafodotin in Daratumumab-Exposed Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/explaining-first-line-options-to-patients-with-egfr-mutated-nsclc</loc>
      <lastmod>2026-11-18T12:05:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T12:05:00Z</news:publication_date>
        <news:title><![CDATA[Explaining First-Line Options to Patients With EGFR-Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/how-the-first-line-egfr-mutated-nsclc-landscape-has-changed</loc>
      <lastmod>2026-11-18T12:00:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T12:00:00Z</news:publication_date>
        <news:title><![CDATA[How the First-Line EGFR-Mutated NSCLC Landscape Has Changed]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/response-based-dosing-and-mutation-testing-guide-ponatinib-use-in-cml</loc>
      <lastmod>2026-11-19T22:34:54.137Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:34:54.137Z</news:publication_date>
        <news:title><![CDATA[Response-Based Dosing and Mutation Testing Guide Ponatinib Use in CML]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/comparing-dasl-hicap-trial-with-enzarad-and-stampede-trials-and-discussion-of-agent-choice</loc>
      <lastmod>2026-11-19T22:15:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:15:00Z</news:publication_date>
        <news:title><![CDATA[Comparing DASL-HiCaP Trial with ENZARAD and STAMPEDE Trials and Discussion of Agent Choice]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/defining-high-risk-localized-prostate-cancer-and-the-dasl-hicap-trial</loc>
      <lastmod>2026-11-19T22:12:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:12:00Z</news:publication_date>
        <news:title><![CDATA[Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/testing-timing-and-toxicity-maximizing-tepotinib-s-durable-benefit-in-met-exon-14-skipping-nsclc</loc>
      <lastmod>2026-11-19T21:46:21.174Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:46:21.174Z</news:publication_date>
        <news:title><![CDATA[Testing, Timing, and Toxicity: Maximizing Tepotinib’s Durable Benefit in MET Exon 14 Skipping NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/ec-approves-extended-cemiplimab-dosing-in-skin-lung-and-cervical-cancers</loc>
      <lastmod>2026-11-19T21:10:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:10:00Z</news:publication_date>
        <news:title><![CDATA[EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dr-janjigian-on-biomarkers-to-guide-first-line-treatment-in-her2-gastroesophageal-cancer</loc>
      <lastmod>2026-11-19T20:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T20:30:00Z</news:publication_date>
        <news:title><![CDATA[Dr Janjigian on Biomarkers to Guide First-Line Treatment in HER2+ Gastroesophageal Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/dose-optimization-evidentiary-bars-patient-selection-shape-trial-design-egfr-her2-mutant-nsclc</loc>
      <lastmod>2026-11-19T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-grants-priority-review-to-sonesitatug-vedotin-in-cldn18-2-gastroesophageal-cancer</loc>
      <lastmod>2026-11-19T17:19:06.786Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T17:19:06.786Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/induction-chemoimmunotherapy-ctdna-point-beyond-pacific-unresectable-stage-iii-nsclc</loc>
      <lastmod>2026-11-19T15:14:34.403Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:14:34.403Z</news:publication_date>
        <news:title><![CDATA[Induction Chemoimmunotherapy and ctDNA Point Beyond PACIFIC in Unresectable Stage III NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/revisit-every-onclive-on-air-episode-from-october-2026</loc>
      <lastmod>2026-11-19T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Revisit Every OncLive On Air Episode From October 2026]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/sclc-treatment-advances-compound-with-egfr--and-kras-directed-nsclc-updates-at-esmo-2026</loc>
      <lastmod>2026-11-19T14:54:22.903Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:54:22.903Z</news:publication_date>
        <news:title><![CDATA[SCLC Treatment Advances Compound With EGFR- and KRAS-Directed NSCLC Updates at ESMO 2026]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/bridging-therapy-considerations-in-dlbcl-before-car-t-cell-therapy</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Bridging Therapy Considerations in DLBCL Before CAR T-Cell Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/unmet-needs-after-immunotherapy-in-endometrial-cancer</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Unmet Needs After Immunotherapy in Endometrial Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/bridging-therapy-before-car-t-cell-therapy-in-dlbcl</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Bridging Therapy Before CAR T-Cell Therapy in DLBCL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/her2-expression-levels-carcinosarcoma-and-tumor-heterogeneity</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[HER2 Expression Levels, Carcinosarcoma, and Tumor Heterogeneity]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/elticertinib-receives-fda-fast-track-designation-in-egfr-exon-20-mutated-nsclc</loc>
      <lastmod>2026-11-18T22:11:09.658Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:11:09.658Z</news:publication_date>
        <news:title><![CDATA[Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-daretabart-for-newly-diagnosed-high-risk-neuroblastoma</loc>
      <lastmod>2026-11-18T21:55:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:55:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High-Risk Neuroblastoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/exploratory-insights-into-early-tolerability-and-treatment-experience-with-vyloy-zolbetuximab-clzb-in-spotlight-and-glow</loc>
      <lastmod>2026-11-18T19:24:02.712Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:24:02.712Z</news:publication_date>
        <news:title><![CDATA[Exploratory Insights into Early Tolerability and Treatment Experience with VYLOY® (zolbetuximab-clzb) in SPOTLIGHT and GLOW]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/can-ai-fix-clinical-trial-access-in-oncology-arturo-loaiza-bonilla-md-built-the-answer-with-the-data-to-back-it</loc>
      <lastmod>2026-11-18T18:51:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:51:00Z</news:publication_date>
        <news:title><![CDATA[Can AI Fix Clinical Trial Access in Oncology? Arturo Loaiza-Bonilla, MD, Built the Answer With the Data to Back It ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/longitudinal-community-training-helps-prepare-oncology-fellows-for-their-future-careers</loc>
      <lastmod>2026-11-18T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future Careers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.onclive.com/view/natalee-dellphi-305-interpath-001-and-litespark-012-headline-key-oncology-data-from-esmo-2026</loc>
      <lastmod>2026-11-18T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>OncLive</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:00:00Z</news:publication_date>
        <news:title><![CDATA[NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026]]></news:title>
      </news:news>
	</url></urlset>